CCL5 and prostate cancer: This is supported by an animal study of male SCID mice (8–10 weeks old) inoculated with prostate cancer cells (Ace1 or DU145) in the intramedullary cavity of the tibiae compared to saline-inoculated control mice (Sottnik et al., 2015), that reported increased intermedullary pressure exerted by a tumour mass, which induced osteocytes to secrete known promoters of prostate cancer metastasis in bone tissue (CCL5, MMPs).